Literature DB >> 3281725

High-dose cytosine arabinoside and fractionated total-body irradiation: an improved preparative regimen for bone marrow transplantation of children with acute lymphoblastic leukemia in remission.

P F Coccia1, S E Strandjord, P I Warkentin, N K Cheung, E M Gordon, L J Novak, D C Shina, R H Herzig.   

Abstract

Twenty children with acute lymphoblastic leukemia in second (18 patients) or third (two patients) complete remission after bone marrow relapse received allogeneic bone marrow transplants from histocompatible sibling donors. The preparative regimen for marrow transplantation consisted of 12 doses of 3,000 mg/m2 cytosine arabinoside twice daily for six days followed by 1,200 cGy total-body irradiation (six doses of 200 cGy twice daily for three days). The preparative regimen was well tolerated, and all patients showed marrow engraftment promptly. Twelve patients are alive in complete remission 12+ to 79+ months posttransplant; eight patients are over 48 months posttransplant. Six patients died 1 to 9 months posttransplant of nonleukemic causes: (two each of graft-v-host disease, interstitial pneumonitis, and infection). Two patients developed recurrent leukemia at 15 and 30 months posttransplant. Both have died at 19 and 36 months posttransplant. Life table analysis reveals an actuarial survival and event-free survival rate of 58% and a marrow relapse rate of 17%. These results suggest that high-dose cytosine arabinoside and fractionated total-body irradiation is a relatively nontoxic and highly effective preparative regimen for allogeneic bone marrow transplantation for acute lymphoblastic leukemia that deserves further evaluation.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3281725

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  6 in total

1.  Phase 1/2 trial of total marrow and lymph node irradiation to augment reduced-intensity transplantation for advanced hematologic malignancies.

Authors:  Joseph Rosenthal; Jeffrey Wong; Anthony Stein; Dajun Qian; Debbie Hitt; Hossameldin Naeem; Andrew Dagis; Sandra H Thomas; Stephen Forman
Journal:  Blood       Date:  2010-09-28       Impact factor: 22.113

2.  Prevention of cytarabine-induced kerato-conjunctivitis by eye rinse in patients receiving high-dose cytarabine and total body irradiation as a conditioning for hematopoietic stem cell transplantation.

Authors:  Takehiko Mori; Jun Kato; Akiko Yamane; Yoshinobu Aisa; Yusuke Kawata; Mayu Ichimura; Chiaki Tsuneyama; Tomoko Yashima; Yoko Ogawa; Kazuo Tsubota; Naoyuki Shigematsu; Takayuki Shimizu; Shinichiro Okamoto
Journal:  Int J Hematol       Date:  2011-08-19       Impact factor: 2.490

3.  Analysis of the role of hematopoietic stem-cell transplantation in infants with acute lymphoblastic leukemia in first remission and MLL gene rearrangements: a report from the Children's Oncology Group.

Authors:  ZoAnn E Dreyer; Patricia A Dinndorf; Bruce Camitta; Harland Sather; Mei K La; Meenakshi Devidas; Joanne M Hilden; Nyla A Heerema; Jean E Sanders; Ron McGlennen; Cheryl L Willman; Andrew J Carroll; Fred Behm; Franklin O Smith; William G Woods; Kamar Godder; Gregory H Reaman
Journal:  J Clin Oncol       Date:  2010-12-06       Impact factor: 44.544

4.  Intrinsic radiation resistance of primary clonogenic blasts from children with newly diagnosed B-cell precursor acute lymphoblastic leukemia.

Authors:  F M Uckun; W Jaszcz; M Chandan-Langlie; K G Waddick; K Gajl-Peczalska; C W Song
Journal:  J Clin Invest       Date:  1993-03       Impact factor: 14.808

Review 5.  Bone marrow transplantation.

Authors:  T S Vats
Journal:  Indian J Pediatr       Date:  1993 Jul-Aug       Impact factor: 1.967

6.  Efficacy of mouth rinse in preventing oral mucositis in patients receiving high-dose cytarabine for allogeneic hematopoietic stem cell transplantation.

Authors:  Takehiko Mori; Kaori Hasegawa; Ai Okabe; Natsuki Tsujimura; Yusuke Kawata; Tomoko Yashima; Naoko Kobayashi; Sakiko Kondo; Yoshinobu Aisa; Jun Kato; Kazuyuki Tsunoda; Tetsuo Nagai; Taneaki Nakagawa; Naoyuki Shigematsu; Atsushi Kubo; Yasuo Ikeda; Shinichiro Okamoto
Journal:  Int J Hematol       Date:  2008-10-30       Impact factor: 2.490

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.